A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL)-Reference-Cited by-同舟云学术

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL)

Published:2020-06-08 Issue:11 Volume:34 Page:2566-2573
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Seneschal J.¹^ORCID,Lacour J.‐P.²,Bewley A.³,Faurby M.⁴,Paul C.⁵,Pellacani G.⁶,De Simone C.⁷,Horne L.⁸,Sohrt A.⁴,Augustin M.⁹^ORCID,Hammond E.⁸,Reich K.¹⁰^ORCID

Affiliation:

1. Department of Dermatology and Paediatric Dermatology National Reference Centre for Rare Skin Diseases Saint‐André HospitalUniversity of Bordeaux Bordeaux France

2. Department of Dermatology Archet 2 Hospital University Hospital of Nice Nice France

3. Department of Dermatology Barts Health NHS Trust London London UK

4. LEO Pharma A/S Ballerup Denmark

5. Toulouse University and Larrey Hospital Toulouse France

6. Department of Dermatology University of Modena and Reggio Emilia Modena Italy

7. Department of Dermatology Catholic University of the Sacred HeartFondazione Policlinico Universitario “A. Gemelli”, IRCCS Rome Italy

8. AstraZeneca Gaithersburg MD USA

9. Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Centre Hamburg‐Eppendorf (UKE) Hamburg Germany

10. Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and NursingUniversity Medical Center Hamburg‐Eppendorf, and Skinflammation^® Center Hamburg Germany

Funder

LEO Pharma Research Foundation

Amgen

AstraZeneca

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.16568

Reference28 articles.

1. Treating psoriasis with adalimumab